跳到正文
原文
Nature 健康护理主题·· 2026-10-06AI 评分47

后新冠功能障碍性呼吸患者前瞻性病例系列:症状、生活质量及客观呼吸标志物的演变

Evolution of symptoms, quality of life, and objective breathing markers in a prospective case series of patients with post-COVID-19 dysfunctional breathing

AI 导读

本前瞻性病例系列纳入48名确诊为后新冠功能障碍性呼吸(DB)的患者,随访6-9个月。结果显示基线Nijmegen评分≥23的患者比例由68%降至43%(p=0.02),呼吸困难MmRC分级中2至4级患者比例显著下降,生活质量及功能状态有所改善。尽管客观CPET指标如过度通气及呼吸参数离散度等得到改善,47%的患者仍存在显著功能受限。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Dysfunctional breathing (DB) was described after coronavirus disease 2019 (COVID-19) and can contribute to persistent dyspnoea and other associated symptoms but the evolution of DB after COVID-19 is poorly described. Individuals with persistent symptoms after COVID-19 were evaluated and those diagnosed with DB were included. DB was diagnosed by identifying an abnormal breathing pattern during cardiopulmonary exercise testing (CPET) associated with compatible symptoms after ruling out cardiopulmonary conditions that could account for the symptoms. All included patients were prospectively followed and systematically assessed 6–9 months after their diagnosis. Given the multiplicity of analyses and the absence of a pre-specified primary analysis, all findings should be considered exploratory and hypothesis-generating. Forty-eight patients were included and 45 patients were successfully reassessed at 6–9 months. Forty-two received specific respiratory physiotherapy targeting DB. The proportion of individuals with a Nijmegen score ≥ 23 decreased from 30 (68%) at baseline to 19 (43%) at follow-up (p = 0.02). Dyspnea improved at 6–9 months, with 0%, 11%, 44%, 35%, and 11% of patients presenting mMRC grades 0, 1, 2, 3, and 4 at baseline, compared with 20%, 39%, 37%, 4%, and 0% at follow-up (p < 0.001). Improvements in quality of life and functional status were observed. However, 21 patients (47%) continued to experience significant functional limitations, defined as a post-COVID-19 functional status (PCFS) scale score ≥ 2. Objective markers of DB during CPET improved, with reductions in hyperventilation, dispersion of breathing parameters, and the number of sighs. In most patients diagnosed with DB after COVID-19, improvements in symptoms, QoL, functional status and objective markers of DB were observed at 6–9 months. A substantial proportion of patients remained disabled.

Acknowledgements

We thank all patients who participated in this cohort. We thank the Ligue Pulmonaire Genevoise, the Ligue Pulmonaire Valaisanne and the foundation Lancardis for their financial support to develop and adapt methods to measure the dispersion, sighs and entropy during exercise testing34–36.

Funding

This study did not receive any specific grants from public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Service de Pneumologie, Centre Hospitalier du Valais Romand, Sion, Switzerland

    Léon Genecand, Isabelle Frésard, Marco Altarelli, Alzbeta Binkova, Stéphanie Vaudan, Arnaud Rapillard & Pierre-Olivier Bridevaux

  2. Faculty of Medicine, University of Geneva, Geneva, Switzerland

    Léon Genecand & Pierre-Olivier Bridevaux

  3. Service de Pneumologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland

    Léon Genecand & Pierre-Olivier Bridevaux

  4. Service de Physiothérapie, Centre Hospitalier du Valais Romand, Martigny, Switzerland

    Stéphanie Vaudan

  5. Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, FHU Cournand, ERN Lung, Hôpital Bicêtre, Le Kremlin Bicêtre, France

    Antoine Beurnier & David Montani

  6. Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France

    Antoine Beurnier & David Montani

  7. INSERM UMR_S 1358 HPPIT Pulmonary hypertension: pathophysiology and novel therapies, Marie Lannelongue Hospital and Bicêtre Hospital, Le Kremlin-Bicêtre, France

    Antoine Beurnier & David Montani

  8. Centre de Recherche Clinique, hôpitaux Universitaires de Genève, Geneva, Switzerland

    Cyril Jaksic

Authors

  1. Léon Genecand
  2. Isabelle Frésard
  3. Marco Altarelli
  4. Alzbeta Binkova
  5. Stéphanie Vaudan
  6. Arnaud Rapillard
  7. Antoine Beurnier
  8. David Montani
  9. Cyril Jaksic
  10. Pierre-Olivier Bridevaux

Corresponding author

Correspondence to Léon Genecand.

Ethics declarations

Competing interests

The authors have no competing interests.

Informed consent

Patients were involved in the design of the study as discussed previously16.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genecand, L., Frésard, I., Altarelli, M. et al. Evolution of symptoms, quality of life, and objective breathing markers in a prospective case series of patients with post-COVID-19 dysfunctional breathing. Sci Rep (2026). https://doi.org/10.1038/s41598-026-72712-7

Download citation

  • Received: 21 May 2026

  • Accepted: 17 September 2026

  • Published: 06 October 2026

  • DOI: https://doi.org/10.1038/s41598-026-72712-7

Keywords

来源:Nature 健康护理主题 · nature.com